VCYT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Veracyte Inc (VCYT) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance in the latest quarter, coupled with its growth trajectory, outweighs the lack of recent positive trading signals and the neutral sentiment in trading trends. Despite the slight pre-market dip, the company's fundamentals and growth potential make it a solid long-term investment.
The MACD is positive and expanding, indicating bullish momentum. However, RSI is neutral at 46.451, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 32.697, with key support at 31.505 and resistance at 33.889.
Strong financial performance in Q4 2025 with revenue up 18.55% YoY, net income up 704.79% YoY, and EPS up 733.33% YoY. Gross margin also improved by 9.68%.
Morgan Stanley downgraded the price target to $37 from $48 and maintained an Underweight rating. No recent news or significant trading trends from insiders or hedge funds.
In Q4 2025, Veracyte's revenue increased to $140.64M (+18.55% YoY), net income surged to $41.15M (+704.79% YoY), EPS rose to $0.50 (+733.33% YoY), and gross margin improved to 72.07% (+9.68% YoY).
Mixed analyst sentiment. Morgan Stanley lowered the price target to $37 and maintained an Underweight rating, while Guggenheim raised the price target to $50 and maintained a Buy rating.
